Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: Developing treatments using an integrated translational approach

References

• Akimoto T, Kusumi I, Suzuki K, Koyama T. 2007. Effects of calmodulin and protein kinase C modulators on transient Ca2 + increase and capacitative Ca2 + entry in human platelets: relevant to pathophysiology of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 31:136–141.
   PubMed Web of Science ®Google Scholar
• Andreazza AC, Kauer-Sant’Anna M, Frey BN, Bond DJ, Kapczinski F, Young LT, et al. 2008. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Dis 111:135–144.
   PubMed Web of Science ®Google Scholar
• Andreazza AC, Wang JF, Salmasi F, Shao L, Young LT. Specific subcellular changes in oxidative stress in prefrontal cortex from patients with bipolar disorder. J Neurochem 20 May 2013.
   Google Scholar
• Angelucci F, Aloe L, Jiménez-Vasquez P, Mathé AA. 2003. Lithium treatment alters brain concentrations of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor in a rat model of depression. Int J Neuropsychopharmacol 6:225–231.
   PubMed Web of Science ®Google Scholar
• Baum AE, Akula N, Cabanero M, Cardona I, Corona W, Klemens B, et al. 2008. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry 13:197–207.
   PubMed Web of Science ®Google Scholar
• Beaulieu J-M, Gainetdinov RR, Caron MG. 2009. Akt/GSK3 signaling in the action of psychotropic drugs. Ann Rev Pharmacol Toxicol 49:327–347.
   PubMed Web of Science ®Google Scholar
• Benedetti F, Serretti A, Pontiggia A, Bernasconi A, Lorenzi C, Colombo C, et al. 2005. Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. Neurosci Lett 376:51–55.
   PubMed Web of Science ®Google Scholar
• Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, et al. 2011. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 35:804–817.
   PubMed Web of Science ®Google Scholar
• Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. 2000. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351–354.
   PubMed Web of Science ®Google Scholar
• Bora E, Fornito A, Yücel M, Pantelis C. 2010. Voxelwise meta-analysis of gray matter abnormalities in bipolar disorder. Biol Psychiatry. 67:1097–1105.
   PubMed Web of Science ®Google Scholar
• Brennan BP, Hudson JI, Jensen JE, McCarthy J, Roberts JL, Prescot AP, et al. 2010. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology 35:834–846.
   PubMed Web of Science ®Google Scholar
• Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH, et al. 1999b. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 72:879–882.
   PubMed Web of Science ®Google Scholar
• Clay HB, Sillivan S, Konradi C. 2011. Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int J Dev Neurosci. 29:311–324.
   PubMed Web of Science ®Google Scholar
• Cotter DR, Pariante CM, Everall IP. 2001. Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res Bull 55:585–595.
   PubMed Web of Science ®Google Scholar
• Craddock N, Sklar P. 2009. Genetics of bipolar disorder: successful start to a long journey. Trends Genet 25:99–105.
   PubMedGoogle Scholar
• Cui J, Shao L, Young LT, Wang JF. 2007. Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 144:1447–1453.
   PubMed Web of Science ®Google Scholar
• Dager SR, Friedman SD, Parow A, Demopulos C, Stoll AL, Lyoo IK, et al. 2004. Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry 61: 450–458.
   PubMed Web of Science ®Google Scholar
• de Sousa RT, van de Bilt MT, Diniz BS, Ladeira RB, Portela LV, Souza DO, et al. 2011. Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. Neurosci Lett 494:54–56.
   PubMed Web of Science ®Google Scholar
• Debette S, Markus HS. 2010. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. Br Med J 341:c3666.
   PubMed Web of Science ®Google Scholar
• Deep-Soboslay A, Iglesias B, Hyde TM, Bigelow LB, Imamovic V, Herman MM, et al. 2008. Evaluation of tissue collection for postmortem studies of bipolar disorder. Bipolar Disord 10:822–828.
   PubMed Web of Science ®Google Scholar
• Diazgranados N, Zarate CA. 2008. A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder. Curr Psychiatry Rep 10: 510–519.
   Google Scholar
• DiazGranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA, et al. 2010. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 71:1605–1611.
   PubMed Web of Science ®Google Scholar
• Dokucu ME, Yu L, Taghert PH. 2005. Lithium- and valproate-induced alterations in circadian locomotor behavior in Drosophila. Neuropsychopharmacology 30:2216–2224.
   PubMed Web of Science ®Google Scholar
• Drevets WC, Price JL, Simpson JR, Todd RD, Reich T, Vannier M, et al. 1997. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 386:824–827.
   PubMed Web of Science ®Google Scholar
• Frizzo ME, DallfOnder LP, Dalcin KB, Souza DO. 2004. Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell Mol Neurobiol 24:123–128.
   PubMed Web of Science ®Google Scholar
• Genoux D, Montgomery JM. 2007. Glutamate receptor plasticity at excitatory synapses in the brain. Clin Exp Pharmacol Physiol 34:1058–1063.
   Google Scholar
• Gigante AD, Young LT, Yatham LN, Andreazza AC, Nery FG, Grinberg LT, et al. 2011. Morphometric post-mortem studies in bipolar disorder: possible association with oxidative stress and apoptosis. Int J Neuropsychopharmacol 14:1075–1089.
   PubMed Web of Science ®Google Scholar
• Goodwin FK, Jamison KR. 2007. Manic-depressive illness: Bipolar and recurrent unipolar disorders. New York: Oxford University Press.
   Google Scholar
• Grande I, Fries GR, Kunz M, Kapczinski F. 2010. The role of BDNF as a mediator of neuroplasticity in bipolar disorder. Psychiatry Investg 7:243–250.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Koizumi H, Nakazato M, Shimizu E, Iyo M. 2005. Role of brain-derived neurotrophic factor in eating disorders: recent findings and its pathophysiological implications. Prog Neuropsychopharmacol Biol Psychiatry 29:499–504.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Sawa A, Iyo M. 2007. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 62:1310–1316.
   PubMed Web of Science ®Google Scholar
• Hirayasu Y, Shenton ME, Salisbury DF, Kwon JS, Wible CG, Fischer IA, et al. 1999. Subgenual cingulate cortex volume in first-episode psychosis. Am J Psychiatry 156:1091–1093.
   PubMed Web of Science ®Google Scholar
• Ibrahim L, Diazgranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P, et al. 2012a. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 37:1526–1533.
   PubMed Web of Science ®Google Scholar
• Ibrahim L, Diaz Granados N, Jolkovsky L, Brutsche N, Luckenbaugh DA, Herring WJ, et al. 2012b. A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol. 32:551–557.
   PubMed Web of Science ®Google Scholar
• Jope RS. 2011. Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Front Mol Neurosci 4:16.
   PubMed Web of Science ®Google Scholar
• Jope RS, Roh M-S. 2006. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets 7:1421–1434.
   PubMed Web of Science ®Google Scholar
• Kakiuchi C, Iwamoto K, Ishiwata M, Bundo M, Kasahara T, Kusumi I, et al. 2003. Impaired feedback regulation of XBP1 as a genetic risk factor for bipolar disorder. Nat Genet 35:171–175.
   PubMed Web of Science ®Google Scholar
• Kapczinski F, Frey BN, Kauer-Sant’Anna M, Grassi-Oliveira R. 2008. Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert Rev Neurother 8:1101–1113.
   PubMedGoogle Scholar
• Kato T, Ishiwata M, Mori K, Washizuka S, Tajima O, Akiyama T, et al. 2003. Mechanisms of altered Ca2 + signalling in transformed lymphoblastoid cells from patients with bipolar disorder. Int J Neuropsychopharmacol 6:379–389.
   PubMed Web of Science ®Google Scholar
• Kato T, Takahashi S, Shioiri T, Inubushi T. 1993. Alterations in brain phosphorous metabolism in bipolar disorder detected by in vivo 31P and 7Li magnetic resonance spectroscopy. J Affect Disord 27:53–59.
   PubMed Web of Science ®Google Scholar
• Kato T, Takahashi S, Shioiri T, Murashita J, Hamakawa H, Inubushi T. 1994. Reduction of brain phosphocreatine in bipolar II disorder detected by phosphorus-31 magnetic resonance spectroscopy. J Affect Disord 31:125–133.
   PubMed Web of Science ®Google Scholar
• Kempton MJ, Geddes JR, Ettinger U, Williams SCR, Grasby PM. 2008. Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. Arch Gen Psychiatry 65:1017–1032.
   PubMed Web of Science ®Google Scholar
• Khairova R, Pawar R, Salvadore G, Juruena MF, de Sousa RT, Soeiro-de-Souza MG, et al. 2012. Effects of lithium on oxidative stress parameters in healthy subjects. Mol Med Rep 5:680–682.
   PubMed Web of Science ®Google Scholar
• Konradi C, Sillivan SE, Clay HB. 2012. Mitochondria, oligodendrocytes and inflammation in bipolar disorder: evidence from transcriptome studies points to intriguing parallels with multiple sclerosis. Neurobiol Dis 45:37–47.
   PubMed Web of Science ®Google Scholar
• Kraguljac NV, Reid M, White D, Jones R, den Hollander J, Lowman D, et al. 2012. Neurometabolites in schizophrenia and bipolar disorder – a systematic review and meta–analysis. Psychiatry Res 203:111–125.
   PubMed Web of Science ®Google Scholar
• Li X, Jope RS. 2010. Is glycogen synthase kinase-3 a central modulator in mood regulation?. Neuropsychopharmacology 35:2143–2154.
   PubMed Web of Science ®Google Scholar
• Lim CS, Baldessarini RJ, Vieta E, Yucel M, Bora E, Sim K. 2013. Longitudinal neuroimaging and neuropsychological changes in bipolar disorder patients: Review of the evidence. Neurosci Biobehav Rev.
   Google Scholar
• Liu ME, Huang CC, Yang AC, Tu PC, Yeh HL, Hong CJ, et al. 2013. Effect of Bcl-2 rs956572 polymorphism on age-related gray matter volume changes. PLoS One 8:e56663..
   Google Scholar
• Lyoo IK, Sung YH, Dager SR, Friedman SD, Lee J-Y, Kim SJ, et al. 2006. Regional cerebral cortical thinning in bipolar disorder. Bipolar Disord 8:65–74.
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Andreazza AC, Viale CI, Zanatto V, Cereser V, da Silva Vargas R, et al. 2007a. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 421:33–36.
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Dietrich MO, Leke R, Cereser VH, Zanatto V, Kapczinski F, et al. 2007b. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry 61:142–144.
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Manji HK, Zarate CA. 2009a. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord 11(Suppl 2):92–109.
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Salvadore G, Diazgranados N, Zarate CA Jr. 2009b. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 123:143–50.
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Pivovarova NB, Stanika RI, Yuan P, Wang Y, Zhou R, et al. 2011. The Bcl-2 gene polymorphism rs956572AA increases inositol 1,4,5-trisphosphate receptor-mediated endoplasmic reticulum calcium release in subjects with bipolar disorder. Biol Psychiatry 69:344–352.
   PubMedGoogle Scholar
• Machado-Vieira R, Ibrahim L, Henter ID, Zarate CA Jr. 2012. Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol Biochem Behav 100:678–87.
   Google Scholar
• Maddock RJ, Buonocore MH. 2012. MR Spectroscopic studies of the brain in psychiatric disorders. Curr Top Behav Neurosci 1 Feb [Epub ahead of print].
   Google Scholar
• Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RMA, Petukhova M, et al. 2007. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 64:543–552.
   PubMed Web of Science ®Google Scholar
• Mizuta I, Ohta M, Ohta K, Nishimura M, Mizuta E, Kuno S. 2001. Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neurosci Lett 310:117–120.
   PubMed Web of Science ®Google Scholar
• Mocchetti I, Brown M. 2008. Targeting neurotrophin receptors in the central nervous system. CNS Neurol Disord Drug Targets 7:71–82.
   Google Scholar
• Moore GJ, Cortese BM, Glitz DA, Zajac-Benitez C, Quiroz JA, Uhde TW, et al. 2009. A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J Clin Psychiatry 70:699–705.
   PubMed Web of Science ®Google Scholar
• Munkholm K, Vinberg M, Berk M, Kessing LV. 2012. State- related alterations of gene expression in bipolar disorder: a systematic review. Bipolar Disord 14:684–696.
   PubMedGoogle Scholar
• Nierenberg AA, Kansky C, Brennan BP, Shelton RC, Perlis R, Iosifescu DV. 2013. Mitochondrial modulators for bipolar disorder: a pathophysiologically informed paradigm for new drug development. Aust NZ J Psychiatry 47:26–42.
   Google Scholar
• Nurnberger JI, Foroud T. 2000. Genetics of bipolar affective disorder. Curr Psychiatry Rep 2:147–157.
   PubMedGoogle Scholar
• Ongur D, Jensen JE, Prescot AP, Stork C, Lundy M, Cohen BM, et al. 2008. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry 64:718–726.
   PubMed Web of Science ®Google Scholar
• Peng TI, Jou MJ. 2010. Oxidative stress caused by mitochondrial calcium overload. Ann NY Acad Sci 1201:183–188.
   PubMed Web of Science ®Google Scholar
• Port JD, Unal SS, Mrazek DA, Marcus SM. 2008. Metabolic alterations in medication-free patients with bipolar disorder: a 3T CSF-corrected magnetic resonance spectroscopic imaging study. Psychiatry Res 162:113–121.
   Google Scholar
• Psychiatric GWAS Consortium Bipolar Disorder Working Group. 2011. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet 43:977–983.
   PubMed Web of Science ®Google Scholar
• Quiroz JA, Gray NA, Kato T, Manji HK. 2008. Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 33:2551–2565.
   PubMed Web of Science ®Google Scholar
• Quiroz JA, Machado-Vieira R, Zarate CA Jr, Manji HK. 2010. Novel insights into lithium’s mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology 62:50–60
   PubMed Web of Science ®Google Scholar
• Schneider MR, DelBello MP, McNamara RK, Strakowski SM, Adler CM. 2012. Neuroprogression in bipolar disorder. Bipolar Disord 14:356–374.
   PubMed Web of Science ®Google Scholar
• Scott LJ, Muglia P, Kong XQ, Guan W, Flickinger M, Upmanyu R, et al. 2009. Genome-wide association and meta-analysis of bipolar disorder in individuals of European ancestry. Proc Natl Acad Sci USA 106:7501–7506.
   PubMed Web of Science ®Google Scholar
• Seifuddin F, Mahon PB, Judy J, Pirooznia M, Jancic D, Taylor J, et al. 2012. Meta-analysis of genetic association studies on bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 159B:508–518.
   PubMed Web of Science ®Google Scholar
• Selemon LD, Rajkowska G. 2003. Cellular pathology in the dorsolateral prefrontal cortex distinguishes schizophrenia from bipolar disorder. Curr Mol Med 3:427–436.
   PubMed Web of Science ®Google Scholar
• Shao L, Young LT, Wang J-F. 2005. Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol Psychiatry 58:879–884.
   PubMed Web of Science ®Google Scholar
• Shao L, Sun X, Xu L, Young LT, Wang J-F. 2006. Mood stabilizing drug lithium increases expression of endoplasmic reticulum stress proteins in primary cultured rat cerebral cortical cells. Life Sci 78:1317–1323.
   PubMed Web of Science ®Google Scholar
• Sharma V, Menon R, Carr TJ, Densmore M, Mazmanian D, Williamson PC. 2003. An MRI study of subgenual prefrontal cortex in patients with familial and non–familial bipolar I disorder. J Affect Disord 77:167–171.
   PubMed Web of Science ®Google Scholar
• Skaper SD. 2008. The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. CNS Neurol Disord Drug Targets 7:46–62.
   PubMed Web of Science ®Google Scholar
• So J, Warsh JJ, Li PP. 2007. Impaired endoplasmic reticulum stress response in B-lymphoblasts from patients with bipolar-I disorder. Biol Psychiatry 62:141–147.
   Google Scholar
• Soeiro-de-Souza MG, Dias VV, Figueira ML, Forlenza OV, Gattaz WF, Zarate CA, et al. 2012. Translating neurotrophic and cellular plasticity: from pathophysiology to improved therapeutics for bipolar disorder. Acta Psychiatr Scand 126: 332–341.
   PubMed Web of Science ®Google Scholar
• Sourial-Bassillious N, Rydelius P-A, Aperia A, Aizman O. 2009. Glutamate-mediated calcium signaling: a potential target for lithium action. Neuroscience 161:1126–1134.
   PubMed Web of Science ®Google Scholar
• Szabo ST, Machado-Vieira R, Yuan P, Wang Y, Wei Y, Falke C, et al. 2009. Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania. Neuropharmacology 56:47–55.
   Google Scholar
• Torgerson CM, Irimia A, Leow AD, Bartzokis G, Moody TD, Jennings RG, et al. 2012. DTI tractography and white matter fiber tract characteristics in euthymic bipolar I patients and healthy control subjects. Brain Imaging Behav 7:129–139.
   Google Scholar
• Vederine F-E, Wessa M, Leboyer M, Houenou J. 2011. A meta-analysis of whole-brain diffusion tensor imaging studies in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 35:1820–1826.
   PubMed Web of Science ®Google Scholar
• Weber H, Kittel-Schneider S, Gessner A, Domschke K, Neuner M, Jacob CP, et al. 2011. Cross-disorder analysis of bipolar risk genes: further evidence of DGKH as a risk gene for bipolar disorder, but also unipolar depression and adult ADHD. Neuropsychopharmacology 36:2076–2085.
   PubMed Web of Science ®Google Scholar
• Yan X-B, Hou H-L, Wu L-M, Liu J, Zhou J-N. 2007. Lithium regulates hippocampal neurogenesis by ERK pathway and facilitates recovery of spatial learning and memory in rats after transient global cerebral ischemia. Neuropharmacology 53: 487–495.
   PubMed Web of Science ®Google Scholar
• Yin L, Wang J, Klein PS, Lazar MA. 2006. Nuclear receptor Rev-erbalpha is a critical lithium-sensitive component of the circadian clock. Science 311:1002–1005.
   PubMed Web of Science ®Google Scholar
• Yüksel C, Ongur D. 2010. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry 68:785–794.
   PubMed Web of Science ®Google Scholar
• Zarate CA, Manji HK. 2009. Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder. CNS Drugs 23:569–582.
   PubMed Web of Science ®Google Scholar
• Zarate CA, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, et al. 2005. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 57:430–432.
   PubMed Web of Science ®Google Scholar
• Zarate CA, Singh J, Manji HK. 2006a. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry 59:1006–1020.
   PubMed Web of Science ®Google Scholar
• Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. 2006b. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–864.
   PubMed Web of Science ®Google Scholar
• Zarate CA, Singh JB, Carlson PJ, Quiroz J, Jolkovsky L, Luckenbaugh DA, et al. 2007. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord 9:561–570.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Machado-Vieira R, Henter I, Ibrahim L, Diazgranados N, Salvadore G. 2010. Glutamatergic modulators: the future of treating mood disorders?Harv Rev Psychiatry 18:293–303.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, et al. 2012. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 71:939–46.
   PubMed Web of Science ®Google Scholar